Maria-Rosa Sarrias

List of Publications by Year
in descending order

48	2,502	147566	197535
papers	citations	31 h-index	49 g-index

54	54	54	4109
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. Cancers, 2022, 14, 440.	1.7	20
2	Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators. Frontiers in Immunology, 2022, 13, 842996.	2.2	11
3	Multifaceted Roles of CD5L in Infectious and Sterile Inflammation. International Journal of Molecular Sciences, 2021, 22, 4076.	1.8	19
4	Role of the Scavenger Receptor CD36 in Accelerated Diabetic Atherosclerosis. International Journal of Molecular Sciences, 2020, 21, 7360.	1.8	15
5	The Circulating Fatty Acid Transporter Soluble CD36 Is Not Associated with Carotid Atherosclerosis in Subjects with Type 1 and Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2020, 9, 1700.	1.0	4
6	Transcriptomic identification of TMIGD1 and its relationship with the ileal epithelial cell differentiation in Crohnâ€™s disease. American Journal of Physiology - Renal Physiology, 2020, 319, G109-G120.	1.6	9
7	Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. Journal of Hepatology, 2020, 73, 328-341.	1.8	82
8	Circulating Soluble CD36 is Similar in Type 1 and Type 2 Diabetes Mellitus versus Non-Diabetic Subjects. Journal of Clinical Medicine, 2019, 8, 710.	1.0	16
9	CD5L is a pleiotropic player in liver fibrosis controlling damage, fibrosis and immune cell content. EBioMedicine, 2019, 43, 513-524.	2.7	28
10	Hepatocellular carcinoma: Present and future. Medicina ClÃnica (English Edition), 2018, 150, 390-397.	0.1	14
11	Low doses of LPS exacerbate the inflammatory response and trigger death on TLR3-primed human monocytes. Cell Death and Disease, 2018, 9, 499.	2.7	38
12	Carcinoma hepatocelular: presente y futuro. Medicina ClÃnica, 2018, 150, 390-397.	0.3	35
13	CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78). FASEB Journal, 2018, 32, 3878-3891.	0.2	43
14	CD5L Promotes M2 Macrophage Polarization through Autophagy-Mediated Upregulation of ID3. Frontiers in Immunology, 2018, 9, 480.	2.2	74
15	A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis. Frontiers in Immunology, 2018, 9, 798.	2.2	47
16	The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism. Cell Reports, 2017, 18, 1241-1255.	2.9	85
17	Pentraxinâ€3 modulates lipopolysaccharideâ€induced inflammatory response and attenuates liver injury. Hepatology, 2017, 66, 953-968.	3.6	39
18	Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine. Theranostics, 2017, 7, 270-284.	4.6	155

#	Article	IF	Citations
19	The human CD5L/AIM-CD36 axis: A novel autophagy inducer in macrophages that modulates inflammatory responses. Autophagy, 2015, 11, 487-502.	4.3	78
20	AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease. Journal of Leukocyte Biology, 2015, 98, 173-184.	1.5	104
21	1081 NEW DIAGNOSTIC AND PROGNOSTIC PLASMA BIOMARKERS FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA IDENTIFIED BY PROTEIN PROFILING. Journal of Hepatology, 2013, 58, S443.	1.8	0
22	The Scavenger Protein Apoptosis Inhibitor of Macrophages (AIM) Potentiates the Antimicrobial Response against Mycobacterium tuberculosis by Enhancing Autophagy. PLoS ONE, 2013, 8, e79670.	1.1	44
23	Human scavenger protein AIM increases foam cell formation and CD36-mediated oxLDL uptake. Journal of Leukocyte Biology, 2013, 95, 509-520.	1.5	36
24	Role of scavenger receptors in the pathophysiology of chronic liver diseases. Critical Reviews in Immunology, 2013, , .	1.0	24
25	Role of scavenger receptors in the pathophysiology of chronic liver diseases. Critical Reviews in Immunology, 2013, 33, 57-96.	1.0	31
26	Liver X Receptors Inhibit Macrophage Proliferation through Downregulation of Cyclins D1 and B1 and Cyclin-Dependent Kinases 2 and 4. Journal of Immunology, 2011, 186, 4656-4667.	0.4	25
27	The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1506-1511.	3.3	117
28	Genetic and structural analysis of MBL2 and MASP2 polymorphisms in southâ€eastern African children. Tissue Antigens, 2009, 74, 298-307.	1.0	16
29	CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11724-11729.	3.3	100
30	Crystal Structure of the Third Extracellular Domain of CD5 Reveals the Fold of a Group B Scavenger Cysteine-rich Receptor Domain. Journal of Biological Chemistry, 2007, 282, 12669-12677.	1.6	40
31	Expression, purification and crystallization of human CD5 domain III, a nano-scale crystallization example. Journal of Structural Biology, 2007, 159, 144-148.	1.3	3
32	Identification and Functional Characterization of the Hepatic Stellate Cell CD38 Cell Surface Molecule. American Journal of Pathology, 2007, 170, 176-187.	1.9	44
33	Mitogen-Activated Protein Kinase Pathway Activation by the CD6 Lymphocyte Surface Receptor. Journal of Immunology, 2006, 177, 1152-1159.	0.4	45
34	A Role for Human SPÎ± as a Pattern Recognition Receptor. Journal of Biological Chemistry, 2005, 280, 35391-35398.	1.6	97
35	The Lymphocyte Receptor CD6 Interacts with Syntenin-1, a Scaffolding Protein Containing PDZ Domains. Journal of Immunology, 2005, 175, 1406-1414.	0.4	57
36	Expression of Interleukin-8 Receptors (CXCR1 and CXCR2) in Premenopausal Women with Recurrent Urinary Tract Infections. Vaccine Journal, 2005, 12, 1358-1363.	3.2	40

#	Article	IF	Citations
37	Relevance of CD6-Mediated Interactions in T Cell Activation and Proliferation. Journal of Immunology, 2004, 173, 2262-2270.	0.4	130
38	Biochemical characterization of recombinant and circulating human Spalpha. Tissue Antigens, 2004, 63, 335-344.	1.0	38
39	The Scavenger Receptor Cysteine-Rich (SRCR) Domain: An Ancient and Highly Conserved Protein Module of the Innate Immune System. Critical Reviews in Immunology, 2004, 24, 1-38.	1.0	226
40	Studies of Structure-Activity Relations of Complement Inhibitor Compstatin. Journal of Immunology, 2003, 171, 1881-1890.	0.4	39
41	Cloning and structure of three rainbow trout C3 molecules: a plausible explanation for their functional diversity. Developmental and Comparative Immunology, 2001, 25, 11-24.	1.0	76
42	Structural Studies in Solution of the Recombinant N-Terminal Pair of Short Consensus/Complement Repeat Domains of Complement Receptor Type 2 (CR2/CD21) and Interactions with Its Ligand C3dg. Biochemistry, 2001, 40, 5931-5941.	1.2	55
43	Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface. Journal of Immunology, 2001, 167, 5758-5766.	0.4	49
44	Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220. Journal of Immunology, 2001, 167, 1490-1499.	0.4	72
45	Complement and innate immunity. Immunopharmacology, 2000, 49, 187-198.	2.0	112
46	The three HveA receptor ligands, gD, LT-Î± and LIGHT bind to distinct sites on HveA. Molecular Immunology, 2000, 37, 665-673.	1.0	36
47	Structure, functions, and evolution of the third complement component and viral molecular mimicry. Immunologic Research, 1998, 17, 109-121.	1.3	27
48	Cloning of three trout C3 isoforms: structural, functional, and phylogenetic analysis. Molecular Immunology, 1998, 35, 370.	1.0	3